News of AstraZeneca’s recent Covid-19 partnership agreement with the University of Oxford has echoed around the world. The deal would see the Cambridge-based pharmaceutical giant producing billions of doses of a vaccine currently being trialled at The Jenner Institute in Oxford, at no profit, and effectively bring an end to the global crisis. Meanwhile in Milton Keynes the UK ‘mega lab’, the Lighthouse Laboratory, recently completed its 500,000th Coronavirus test.
This crisis has shown how effectively the UK life sciences industry collaborates, with its response to the global pandemic the fastest in the world. But as marketing opportunities for the UK and the Oxford-Cambridge Arc go, they don’t come much bigger. With epidemiology leading the news each day, we ask how should business and political leaders in Oxford, Cambridge and Milton Keynes be building on the public’s new awareness of the importance of scientific research to both our health and the UK economy?
Listen to hear from Astra Zenenca’s Andy Williams, Chloe French from Bidwells and Advanced Oxford’s MD Sarah Haywood in conversation.
Click here to listen to the podcast
